173 related articles for article (PubMed ID: 32850440)
21. Immune landscape of advanced gastric cancer tumor microenvironment identifies immunotherapeutic relevant gene signature.
Zhang S; Lv M; Cheng Y; Wang S; Li C; Qu X
BMC Cancer; 2021 Dec; 21(1):1324. PubMed ID: 34893046
[TBL] [Abstract][Full Text] [Related]
22. Plasma cell subtypes analyzed using artificial intelligence algorithm for predicting biochemical recurrence, immune escape potential, and immunotherapy response of prostate cancer.
Xie X; Dou CX; Luo MR; Zhang K; Liu Y; Zhou JW; Huang ZP; Xue KY; Liang HY; Ouyang AR; Ma SX; Yang JK; Zhou QZ; Guo WB; Liu CD; Zhao SC; Chen MK
Front Immunol; 2022; 13():946209. PubMed ID: 36569837
[TBL] [Abstract][Full Text] [Related]
23. Identifying Immune-Specific Subtypes of Adrenocortical Carcinoma Based on Immunogenomic Profiling.
Lu Q; Nie R; Luo J; Wang X; You L
Biomolecules; 2023 Jan; 13(1):. PubMed ID: 36671489
[TBL] [Abstract][Full Text] [Related]
24. ncRNA-mediated overexpression of ubiquitin-specific proteinase 13 contributes to the progression of prostate cancer via modulating AR signaling, DNA damage repair and immune infiltration.
Cui X; Yu H; Yao J; Li J; Li Z; Jiang Z
BMC Cancer; 2022 Dec; 22(1):1350. PubMed ID: 36564767
[TBL] [Abstract][Full Text] [Related]
25. Identification and validation of immunotherapy for four novel clusters of colorectal cancer based on the tumor microenvironment.
Zheng X; Ma Y; Bai Y; Huang T; Lv X; Deng J; Wang Z; Lian W; Tong Y; Zhang X; Yue M; Zhang Y; Li L; Peng M
Front Immunol; 2022; 13():984480. PubMed ID: 36389763
[TBL] [Abstract][Full Text] [Related]
26. Classification of Estrogen Receptor-Positive Breast Cancer Based on Immunogenomic Profiling and Validation at Single-Cell Resolution.
Ma X; Chen H; Yang M; Ke Z; Wang M; Huang T; Li L
Front Cell Dev Biol; 2021; 9():722841. PubMed ID: 34621742
[No Abstract] [Full Text] [Related]
27. Identification of LAT/ZAP70 characterized immune subtypes of prostate cancer.
Yu J; Gao W; Gao S; Wen S; Zhao Y; Shang Z; Wang Y; Niu Y
World J Urol; 2022 Nov; 40(11):2817-2824. PubMed ID: 36205741
[TBL] [Abstract][Full Text] [Related]
28. Investigating subtypes of lung adenocarcinoma by oxidative stress and immunotherapy related genes.
Duan G; Huang C; Zhao J; Zhang Y; Zhao W; Dai H
Sci Rep; 2023 Nov; 13(1):20930. PubMed ID: 38017020
[TBL] [Abstract][Full Text] [Related]
29. A novel immunogenomic classification for prognosis in non-small cell lung cancer.
Tang S; Xu L; Wu Z; Wen Q; Li H; Li N
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10951-10964. PubMed ID: 37329462
[TBL] [Abstract][Full Text] [Related]
30. Genotype-immunophenotype analysis reveals the immunogenomic subtype and prognosis of multiple myeloma.
Wang Y; Feng W; Liu P
Carcinogenesis; 2020 Dec; 41(12):1746-1754. PubMed ID: 32278317
[TBL] [Abstract][Full Text] [Related]
31. MT1G, an emerging ferroptosis-related gene: A novel prognostic biomarker and indicator of immunotherapy sensitivity in prostate cancer.
Cheng B; Lai Y; Huang H; Peng S; Tang C; Chen J; Luo T; Wu J; He H; Wang Q; Huang H
Environ Toxicol; 2024 Feb; 39(2):927-941. PubMed ID: 37972062
[TBL] [Abstract][Full Text] [Related]
32. The Association between Immune Infiltration and Clinical Phenotypes and Prognosis of Prostate Cancer.
Hua L; Xia H; Zheng W
Iran J Biotechnol; 2020 Oct; 18(4):e2538. PubMed ID: 34056020
[TBL] [Abstract][Full Text] [Related]
33. DNA damage repair profiling of esophageal squamous cell carcinoma uncovers clinically relevant molecular subtypes with distinct prognoses and therapeutic vulnerabilities.
Zhao N; Zhang Z; Wang Q; Li L; Wei Z; Chen H; Zhou M; Liu Z; Su J
EBioMedicine; 2023 Oct; 96():104801. PubMed ID: 37725855
[TBL] [Abstract][Full Text] [Related]
34. 5 signature genes revealed by single-cell profiling identified unique immune subtypes affecting the prognosis of ovarian cancer.
Xiang SY; Li QK; Yang Z; Yi Q
Eur Rev Med Pharmacol Sci; 2024 Mar; 28(5):2051-2062. PubMed ID: 38497886
[TBL] [Abstract][Full Text] [Related]
35. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
36. A prognostic signature consisting of metabolism-related genes and SLC17A4 serves as a potential biomarker of immunotherapeutic prediction in prostate cancer.
Li H; Gu J; Tian Y; Li S; Zhang H; Dai Z; Wang Z; Zhang N; Peng R
Front Immunol; 2022; 13():982628. PubMed ID: 36325340
[TBL] [Abstract][Full Text] [Related]
37. LTBP2 inhibits prostate cancer progression and metastasis via the PI3K/AKT signaling pathway.
Zhang X; Tian C; Cheng J; Mao W; Li M; Chen M
Exp Ther Med; 2022 Sep; 24(3):563. PubMed ID: 36034756
[TBL] [Abstract][Full Text] [Related]
38. Hierarchical Clustering of Cutaneous Melanoma Based on Immunogenomic Profiling.
Yu J; Xie M; Ge S; Chai P; Zhou Y; Ruan J
Front Oncol; 2020; 10():580029. PubMed ID: 33330057
[TBL] [Abstract][Full Text] [Related]
39. Hypoxia promotes conversion to a stem cell phenotype in prostate cancer cells by activating HIF-1α/Notch1 signaling pathway.
Wu K; Wu M; Yang H; Diao R; Zeng H
Clin Transl Oncol; 2023 Jul; 25(7):2138-2152. PubMed ID: 36757381
[TBL] [Abstract][Full Text] [Related]
40. Identification of Metabolism-Associated Prostate Cancer Subtypes and Construction of a Prognostic Risk Model.
Zhang Y; Zhang R; Liang F; Zhang L; Liang X
Front Oncol; 2020; 10():598801. PubMed ID: 33324566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
